Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
179actual
Sites
28
Countries
France, Germany, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-01-02 | actual | When the study began enrolling |
| Primary completion | 2023-09-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2017-12-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-12-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Myeloproliferative Neoplasm
Intervention
- Drug: IMGN632
Primary outcome
what the primary-completion date above is the date OFTo assess the rate of composite CR in BPDCN patients
measured 21-day cycle
Publications
- PMID 41671533 — linked by the registry
- PMID 38423051 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed